Epigenomics AG reaffirmed revenue guidance for the full year 2022. For the period, the company revenue forecast remains unchanged between EUR 0.3 million to EUR 0.8 million.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1.89 EUR | -.--% | +8.31% | -.--% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-18.88% | 11.03B | |
+53.75% | 3.5B | |
-32.50% | 2.23B | |
-14.31% | 2.16B | |
-26.83% | 1.54B | |
+28.55% | 1.12B | |
-3.28% | 737M | |
-23.50% | 477M | |
-43.27% | 411M |
- Stock Market
- Equities
- ECX Stock
- ECX Stock
- News Epigenomics AG
- Epigenomics Ag Reaffirms Revenue Guidance for the Full Year 2022